Safety Screening Before Psychedelic Therapy: Who Should (and Shouldn't) Try It

# Safety Screening Before Psychedelic Therapy: Who Should (and Shouldn't) Try It

The most important conversation in psychedelic medicine isn't about which compound works best or how dramatic the results are. It's about who should never try it at all.

Every legitimate clinical trial of psychedelic therapy begins with extensive screening — not because researchers are being cautious for liability reasons, but because real contraindications exist and ignoring them can cause serious harm.

Absolute contraindications

These are conditions where psychedelic therapy is universally excluded in clinical research:

Personal history of psychotic disorders: Schizophrenia, schizoaffective disorder, or any history of psychotic episodes is the most critical exclusion. Psychedelics can trigger or worsen psychosis in vulnerable individuals, and this risk is not theoretical — it's well-documented. Even a single psychotic episode in the past is typically disqualifying.

First-degree relative with schizophrenia or psychosis: If a parent or sibling has a psychotic disorder, most trials exclude you even if you've never experienced psychosis yourself. The genetic vulnerability is considered too significant.

Uncontrolled hypertension: Psychedelics cause acute increases in blood pressure and heart rate. For someone with uncontrolled hypertension, this can be dangerous. Well-controlled hypertension on medication is sometimes acceptable, but careful monitoring is required.

Significant cardiovascular disease: Recent heart attack, unstable angina, serious arrhythmias, or other active cardiac conditions are exclusions. The cardiovascular stress of a psychedelic session is real.

Pregnancy or breastfeeding: The effects of psychedelics on fetal development are unknown, and no responsible researcher would expose a developing fetus to these compounds.

Strong relative contraindications

These conditions don't absolutely prevent participation but require careful evaluation and may lead to exclusion:

Bipolar disorder: This is debated. Some researchers include people with bipolar II in carefully monitored settings, while others exclude all bipolar patients. The concern is triggering a manic episode. The risk is likely lower with psilocybin than with ketamine, but it exists.

Active substance use disorder: If someone is currently using drugs or alcohol heavily, adding a psychedelic to the picture creates unpredictable risk. Most trials require a period of sobriety before participation. Ironically, psychedelics show promise for treating addiction — but the initial use needs to happen in a stable, substance-free baseline.

Severe personality disorders: Particularly borderline personality disorder, where the emotional intensity of a psychedelic experience could be destabilizing. Some researchers are beginning to explore psychedelics for BPD, but this is very early territory.

Current SSRI or SNRI use: SSRIs can dampen the psychedelic response (they work on overlapping serotonin pathways) and, with some combinations, theoretically increase serotonin syndrome risk. Most trials require a washout period of 2-6 weeks. This creates its own risk — people tapering off antidepressants can experience significant worsening of depression during the washout.

Lithium: The combination of lithium and psychedelics is considered high-risk for seizures. This is one of the firmest drug interaction concerns in the field.

What the screening process looks like

In a well-run clinical setting, screening includes:

1. Detailed psychiatric history: Not just current diagnosis, but lifetime history of all mental health conditions, hospitalizations, and medication trials
2. Family psychiatric history: Specifically looking for psychotic disorders in first-degree relatives
3. Medical history and physical exam: Cardiovascular evaluation, current medications, allergies
4. Lab work: Basic metabolic panel, liver function, thyroid function, sometimes cardiac enzymes or EKG
5. Psychological assessment: Standardized measures of depression, anxiety, personality, and psychosis vulnerability
6. Substance use assessment: Current and historical substance use patterns
7. Informed consent: Detailed discussion of risks, benefits, alternatives, and what the experience may involve

This process typically takes 2-4 weeks and multiple appointments.

The medications that interact

Beyond SSRIs and lithium, several medication classes have important interactions with psychedelics:

• MAOIs: Can dangerously potentiate psychedelic effects (especially with DMT/ayahuasca)
• Tramadol: Increases seizure risk in combination with psychedelics
• Stimulants: Can increase cardiovascular stress during sessions
• Antipsychotics: Block psychedelic effects entirely (they're serotonin 2A antagonists)
• Benzodiazepines: Can diminish the psychedelic experience and may be used as "rescue medication" if needed

Why this matters right now

As psychedelic therapy moves from research labs toward wider availability, the quality of safety screening will determine whether this field succeeds or fails.

The worst-case scenario isn't that psychedelics don't work — it's that inadequate screening allows someone with an undiagnosed vulnerability to have a catastrophic reaction, generating headlines that set the entire field back by years.

Every provider, researcher, and advocate in this space has a responsibility to take screening seriously — not as a bureaucratic hurdle but as the foundation that makes everything else possible.

If you're interested in psychedelic therapy, the screening process should be reassuring, not frustrating. A provider who skips it or rushes through it is a provider to avoid.

---

This article is for educational purposes. Dr. Kim does not offer psychedelic-assisted therapy but believes informed patient education is essential as this field develops. For current mental health care, [talk to us](/intake/mental-health).